-
1
-
-
0030982989
-
Therapies for sepsis. Emerging therapies for sepsis and septic shock
-
(1997)
West J Med
, vol.166
, pp. 195-200
-
-
Abraham, E.1
-
4
-
-
0027531731
-
Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC)
-
(1993)
Clin Exp Immunol
, vol.91
, pp. 295-300
-
-
Mollnes, T.E.1
Redl, H.2
Hogasen, K.3
Bengtsson, A.4
Garred, P.5
Speilberg, L.6
Lea, T.7
Oppermann, M.8
Gotze, O.9
Schlag, G.10
-
7
-
-
0027945044
-
Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial
-
BN 52021 Sepsis Study Group
-
(1994)
Crit Care Med
, vol.22
, pp. 1720-1728
-
-
Dhainaut, J.F.1
Tenaillon, A.2
Le Tulzo, Y.3
Schlemmer, B.4
Solet, J.P.5
Wolff, M.6
Holzapfel, L.7
Zeni, F.8
Dreyfuss, D.9
Mira, J.P.10
-
10
-
-
0031023828
-
Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet-activating factor receptor
-
(1997)
EMBO J
, vol.16
, pp. 133-142
-
-
Ishii, S.1
Nagase, T.2
Tashiro, F.3
Ikuta, K.4
Sato, S.5
Waga, I.6
Kume, K.7
Miyazaki, J.8
Shimizu, T.9
-
17
-
-
13344270905
-
Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081
-
(1996)
J Immunol
, vol.156
, pp. 2221-2230
-
-
Van Zee, K.J.1
Moldawer, L.L.2
Oldenburg, H.A.S.3
Thompson, W.Z.4
Stackpole, S.A.5
Montegut, W.J.6
Rogy, M.A.7
Meschter, C.8
Gallati, H.9
Schiller, C.D.10
-
26
-
-
0030951146
-
p38 mitogen-activated protein kinase down-regulates nitric oxide and up-regulates prostaglandin E2 biosynthesis stimulated by interleukin-1β
-
(1997)
J Biol Chem
, vol.272
, pp. 8083-8089
-
-
Guan, Z.1
Baier, L.D.2
Morrison, A.R.3
-
28
-
-
0029979369
-
Biological basis for interleukin-1 in disease
-
(1996)
Blood
, vol.87
, pp. 2095-2147
-
-
Dinarello, C.A.1
-
31
-
-
0028222122
-
Interferon gamma receptor deficient mice are resistant to endotoxic shock
-
(1994)
J Exp Med
, vol.179
, pp. 1437-1444
-
-
Car, B.D.1
Eng, V.M.2
Schnyder, B.3
Ozmen, L.4
Huang, S.5
Gallay, P.6
Heumann, D.7
Aguet, M.8
Ryffel, B.9
-
33
-
-
0031264674
-
Anti-interleukin-12 therapy protects mice in lethal endotoxemia but impairs bacterial clearance in murine Escherichia coli peritoneal sepsis
-
(1997)
Shock
, vol.8
, pp. 349-356
-
-
Zisman, D.A.1
Kunkel, S.L.2
Strieter, R.M.3
Gauldie, J.4
Tsai, W.C.5
Bramson, J.6
Wilkowski, J.M.7
Bucknell, K.A.8
Standiford, T.J.9
-
34
-
-
0029143676
-
MIF as a glucocorticoid-induced modulator of cytokine production
-
(1995)
Nature
, vol.377
, pp. 68-71
-
-
Calandra, T.1
Bernhagen, J.2
Metz, C.N.3
Spiegel, L.A.4
Bacher, M.5
Donnelly, T.6
Cerami, A.7
Bucala, R.8
-
37
-
-
0027478367
-
Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia
-
(1993)
J Exp Med
, vol.177
, pp. 547-550
-
-
Gerard, C.1
Bruyns, C.2
Marchant, A.3
Abramowicz, D.4
Vandenabeele, P.5
Delvaux, A.6
Fiers, W.7
Goldman, M.8
Velu, T.9
-
38
-
-
0028336730
-
Leukocytosis and resistance to septic shock in intercellular adhesion molecule 1-deficient mice
-
(1994)
J Exp Med
, vol.180
, pp. 95-109
-
-
Xu, H.1
Gonzalo, J.A.2
St Pierre, Y.3
Williams, I.R.4
Kupper, T.S.5
Cotran, R.S.6
Springer, T.A.7
Gutierrez-Ramos, J.C.8
-
40
-
-
0029063934
-
Prevention of endotoxin shock by an antibody against leukocyte integrin beta 2 through inhibiting production and action of TNF
-
(1995)
Int Immunol
, vol.7
, pp. 1037-1046
-
-
Watanabe, S.1
Mukaida, N.2
Ikeda, N.3
Akiyama, M.4
Harada, A.5
Nakanishi, I.6
Nariuchi, H.7
Watanabe, Y.8
Matsushima, K.9
-
47
-
-
0026780301
-
Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: A prospective double-blind study
-
(1992)
J Infect Dis
, vol.165
, pp. 695-701
-
-
-
48
-
-
0026016470
-
Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: A randomized, double-blind placebo-controlled trial
-
(1991)
N Engl J Med
, vol.324
, pp. 429-436
-
-
-
49
-
-
0029043636
-
A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial
-
(1995)
Crit Care Med
, vol.23
, pp. 994-1006
-
-
Bone, R.C.1
Balk, R.A.2
Fein, A.M.3
Perl, T.M.4
Wenzel, R.P.5
Reines, H.D.6
Quenzer, R.W.7
Iberti, T.J.8
MacIntyre, N.9
Schein, R.M.10
-
56
-
-
0028924148
-
Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats
-
(1995)
J Clin Invest
, vol.95
, pp. 1947-1952
-
-
Jin, H.1
Yang, R.2
Marsters, S.3
Ashkenazi, A.4
Bunting, S.5
Marra, M.N.6
Scott, R.W.7
Baker, J.B.8
-
57
-
-
0028327687
-
The role of bactericidal/permeability-increasing protein in the treatment of primate bacteremia and septic shock
-
(1994)
J Clin Immunol
, vol.14
, pp. 120-133
-
-
Rogy, M.1
Oldenburg, H.S.2
Calvano, S.E.3
Montegut, W.J.4
Stackpole, S.A.5
Van Zee, K.J.6
Marra, M.7
Scott, R.8
Seilhammer, J.J.9
Moldawer, L.L.10
Lowry, S.F.11
-
58
-
-
0031583752
-
Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis
-
(1997)
Lancet
, vol.350
, pp. 1439-1443
-
-
Giroir, B.P.1
Quint, P.A.2
Barton, P.3
Kirsch, E.A.4
Kitchen, L.5
Goldstein, B.6
Nelson, B.J.7
Wedel, N.J.8
Carroll, S.F.9
Scannon, P.J.10
-
59
-
-
0027236079
-
Comparison of peripheral blood leukocyte kinetics after live Escherichia coli, endotoxin, or interleukin-1 alpha administration. Studies using a novel interleukin-1 receptor antagonist
-
(1993)
Ann Surg
, vol.218
, pp. 79-90
-
-
Hawes, A.S.1
Fischer, E.2
Marano, M.A.3
Van Zee, K.J.4
Rock, C.S.5
Lowry, S.F.6
Calvano, S.E.7
Moldawer, L.L.8
-
60
-
-
0026772736
-
Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia
-
(1992)
J Clin Invest
, vol.89
, pp. 1551-1557
-
-
Fischer, E.1
Marano, M.A.2
Van Zee, K.J.3
Rock, C.S.4
Hawes, A.S.5
Thompson, W.A.6
DeForge, L.7
Kenney, J.S.8
Remick, D.G.9
Bloedow, D.C.10
-
61
-
-
0028018567
-
Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled multicenter trial
-
The IL-1RA Sepsis Syndrome Study Group
-
(1994)
Crit Care Med
, vol.22
, pp. 12-21
-
-
Fisher C.J., Jr.1
Slotman, G.J.2
Opal, S.M.3
Pribble, J.P.4
Bone, R.C.5
Emmanuel, G.6
Ng, D.7
Bloedow, D.C.8
Catalano, M.A.9
-
62
-
-
0028239555
-
Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial
-
Phase III rhIL-1ra Sepsis Syndrome Study Group
-
(1994)
JAMA
, vol.271
, pp. 1836-1843
-
-
Fisher C.J., Jr.1
Dhainaut, J.F.2
Opal, S.M.3
Pribble, J.P.4
Balk, R.A.5
Slotman, G.J.6
Iberti, T.J.7
Rackow, E.C.8
Shapiro, M.J.9
Greenman, R.L.10
-
63
-
-
0030877935
-
The confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III randomized, double-blind, placebo-controlled, multicenter trial
-
(1997)
Crit Care Med
, vol.25
, pp. 1115-1124
-
-
Opal, S.M.1
Fisher, C.J.2
Pribble, J.P.3
Dhainaut, J.-F.4
Vincent, J.-L.5
Brase, R.6
Lowry, S.F.7
Sadoff, J.C.8
Slotman, G.J.9
Levy, H.10
Balk, R.A.11
Shelly, M.P.12
LaBrecque, J.F.13
Lookabaugh, J.14
Donovan, H.15
Baughman, R.16
Norman, J.17
DeMaria, E.18
Matzel, K.19
Abraham, E.20
Seneff, M.21
more..
-
64
-
-
0026481128
-
Lethal S. aureus shock in primates: Prevention of death with anti-TNF antibody
-
(1992)
J Trauma
, vol.33
, pp. 568-573
-
-
Hinshaw, L.B.1
Emerson T.E., Jr.2
Taylor F.B., Jr.3
Chang, A.C.K.4
Duerr, M.5
Peer, G.T.6
Flournoy, D.J.7
White, G.L.8
Kosanake, S.D.9
Murray, C.K.10
Xu, R.11
Passey, R.B.12
Fournel, M.A.13
-
66
-
-
0029132699
-
CDP571, a humanized antibody to human tumor necrosis factor-α: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock
-
(1995)
Crit Care Med
, vol.23
, pp. 1461-1469
-
-
Dhainaut, J.-F.A.1
Vincent, J.-L.2
Richard, C.3
Lejeune, P.4
Martin, C.5
Fierobe, L.6
Stephens, S.7
Ney, U.M.8
Sopwith, M.9
-
68
-
-
0029835023
-
INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis
-
(1996)
Crit Care Med
, vol.24
, pp. 1431-1440
-
-
Cohen, J.1
Carlet, J.2
-
69
-
-
0032495658
-
Monoclonal antibody to human tumor necrosis factor alpha (TNF Mab) in the treatment of patients with septic shock: A multi-center, placebo controlled, randomized, double-blind clinical trial
-
(1998)
Lancet
, vol.351
, pp. 929-933
-
-
Abraham, E.1
Anzueto, A.2
Gutierrez, G.3
Tessler, S.4
San Pedro, G.5
Wunderink, R.6
Dal Nogare, A.7
Nasraway, S.8
Berman, S.9
Cooney, R.10
Levy, H.11
Baughman, R.12
Rumbak, M.13
Light, R.B.14
Poole, L.15
Allred, R.16
Constant, J.17
Pennington, J.18
Porter, S.19
-
70
-
-
9344246862
-
Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study
-
(1996)
Crit Care Med
, vol.24
, pp. 733-742
-
-
Reinhart, K.1
Wiegand-Lohnert, C.2
Grimminger, F.3
-
74
-
-
0035100346
-
Lenercept (p55-Tumor Necrosis Factor Receptor Fusion Protein, Ro 45-2081, Tenefuse) patients with severe sepsis or early septic shock. A randomized double-blind placebo-controlled multicenter phase III trial with 1342 patients
-
in press
-
(2001)
Crit Care Med
-
-
Abraham, E.1
Reynaert, M.2
Lew, D.3
Pingleton, S.4
Butler, I.5
Dugemier, I.6
Margolis, B.7
Kudsk, K.8
Zimmerli, W.9
Anderson, P.10
Laterre, P.F.11
Lesslauer, W.12
Cooper, P.13
Burdeska, A.14
Passe, S.15
Modi, M.16
Leighton, A.17
Salgo, M.18
Van der Auwera, P.19
-
75
-
-
0021708124
-
2 levels: Correlation with the hemodynamic and pulmonary changes in gram-negative septic shock
-
(1984)
J Lab Clin Med
, vol.104
, pp. 873-881
-
-
Vadas, P.1
-
76
-
-
0029075934
-
2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine endotoxin shock
-
(1995)
J Pharmacol Exp Ther
, vol.274
, pp. 1254-1262
-
-
Marshall, L.A.1
Hall, R.H.2
Winkler, J.D.3
Badger, A.4
Bolognese, B.5
Roshak, A.6
Flamberg, P.L.7
Sung, C.M.8
Shabot-Fletcher, M.9
Adams, J.L.10
Mayer, R.J.11
-
77
-
-
0023886464
-
Pathogenesis of hypotension in septic shock: Correlation of circulating phospholipase A2 levels with circulatory collapse
-
(1988)
Crit Care Med
, vol.16
, pp. 1-7
-
-
Vadas, P.1
Pruzanski, W.2
Stefanski, E.3
Sternby, B.4
Mustaqrd, R.5
Bohnen, J.6
Fraser, I.7
Farewell, V.8
Bombardier, C.9
-
78
-
-
0029417317
-
Plasma levels of type II phospholipase A2 and cytokine in patients with sepsis
-
(1995)
Res Commun Mol Pathol Pharmacol
, vol.90
, pp. 413-421
-
-
Endo, S.1
Inada, K.2
Nakae, H.3
Takakuwa, T.4
Yamada, Y.5
Suzuki, T.6
Taniguchi, S.7
Yoshida, M.8
Ogawa, M.9
Teraoka, H.10
-
85
-
-
0025242299
-
G-methyl-L-arginine, an inhibitor of nitric oxide synthesis
-
(1990)
Biochem Biophys Res Commun
, vol.172
, pp. 1132-1138
-
-
Kilbourn, R.G.1
Jubran, A.2
Gross, S.S.3
Griffith, O.W.4
Levi, R.5
Adams, J.6
Lodato, R.F.7
-
87
-
-
0026674684
-
W-amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin
-
(1992)
J Exp Med
, vol.176
, pp. 1175-1182
-
-
Cobb, J.P.1
Natanson, C.2
Hoffman, W.D.3
Lodato, R.F.4
Banks, S.5
Koev, C.A.6
Solomon, M.A.7
Elin, R.J.8
Hosseini, J.M.9
Danner, R.L.10
-
91
-
-
0030926515
-
Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14
-
(1997)
Blood
, vol.89
, pp. 4268-4274
-
-
Park, T.1
Creasey, A.2
Wright, S.3
-
94
-
-
0025807728
-
DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage
-
(1991)
Blood
, vol.78
, pp. 364-368
-
-
Taylor, F.B.1
Change, A.C.2
Peer, G.T.3
Mather, T.4
Blick, K.5
Catlett, R.6
Lockhart, M.S.7
Esmon, C.T.8
-
96
-
-
0031590612
-
Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans
-
(1997)
Lancet
, vol.350
, pp. 1590-1593
-
-
Smith, O.P.1
White, B.2
Vaughan, D.3
Rafferty, M.4
Claffey, L.5
Lyons, B.6
Casey, W.7
-
103
-
-
0026710191
-
ACCP/SCCM consensus conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
-
(1992)
Chest
, vol.101
, pp. 1644-1655
-
-
Bone, R.C.1
Balk, R.A.2
Cerra, F.B.3
-
107
-
-
0030954732
-
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
-
(1997)
N Engl J Med
, vol.337
, pp. 1029-1035
-
-
Targan, S.R.1
Hanauer, S.B.2
Van Deventer, S.J.3
Mayer, L.4
Present, D.H.5
Braakman, T.6
DeWoody, K.L.7
Schaible, T.F.8
Rutgeerts, P.J.9
-
108
-
-
0029671297
-
In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects
-
(1996)
J Immunol
, vol.156
, pp. 1646-1653
-
-
Lorenz, H.M.1
Antoni, C.2
Valerius, T.3
Repp, R.4
Grunke, M.5
Schwedtner, N.6
Nusslein, H.7
Woody, J.8
Kalden, J.R.9
Manger, B.10
-
113
-
-
0008021312
-
Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, Deltibant (CP-0127)
-
(1997)
JAMA
, vol.277
, pp. 482-487
-
-
Fein, A.M.1
Bernard, G.R.2
Criner, G.J.3
-
116
-
-
0032433468
-
Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis: A phase III, randomized double-blind, placebo-controlled, multicenter clinical trial
-
(1998)
Crit Care Med
, vol.26
, pp. 1963-1971
-
-
Dhainaut, J.F.1
Tenaillon, A.2
Hemmer, M.3
|